CRY's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 510.12 -- higher than 92.67% of US-listed equities with positive expected earnings growth.
Cryolife Inc's stock had its IPO on February 12, 1993, making it an older stock than 78.17% of US equities in our set.
Price to trailing twelve month operating cash flow for CRY is currently 49.26, higher than 94.03% of US stocks with positive operating cash flow.
Stocks that are quantitatively similar to CRY, based on their financial statements, market capitalization, and price volatility, are VG, OFIX, AMRN, LIND, and QRHC.
CryoLife Inc. engages in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures. The company was founded in 1984 and is based in Kennesaw, Georgia.
CRY Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Cryolife Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Cryolife Inc ranked in the 7th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Cryolife Inc ended up being:
The company's compound free cash flow growth rate over the past 5.78 years comes in at -0.03%; that's greater than only 24.7% of US stocks we're applying DCF forecasting to.
The company has produced more trailing twelve month cash flow than only 15.31% of its sector Healthcare.
Cryolife Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
LHCG, LCTC, CMD, IVC, and PDLI can be thought of as valuation peers to CRY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
It is now my pleasure to introduce your host, Lynn Lewis from Gilmartin Group. Joining me today from CryoLife's management team are Pat Mackin, CEO, and Ashley Lee, CFO. Comments made on this call that look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
ATLANTA, April 30, 2020 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $66.4 million in the first quarter 2020 versus preliminary first quarter 2020 revenues of $65.5 million Total revenues decreased 2% and decreased 1% on a constant currency…